{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:47:30Z","timestamp":1781657250458,"version":"3.54.5"},"reference-count":8,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T00:00:00Z","timestamp":1149552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2006,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Scabies is a very common skin infection in convicts. The SIMSPE Society (Societ\u00e0 Italiana di Medicina e Sanit\u00e0 Penitenziaria) has organized and conducted a multicentre, randomized, comparative, parallel group, investigator\u2010blinded trial to evaluate the efficacy and tolerability of synergized pyrethrins foam (PF) in comparison with benzyl benzoate (BB) lotion.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> A total of 240 convicted patients, enrolled in eight National Jail Institutions, with a clinical diagnosis of scabies, were treated with PF (<jats:italic>n<\/jats:italic>\u00a0=\u00a0120) for three consecutive days or BB (<jats:italic>n<\/jats:italic>\u00a0=\u00a0120) for five consecutive days. Primary study endpoints were the clinical cure rate and the local tolerability. Secondary endpoints were clinical evolution of scabietic lesions and itching intensity. Study outcomes were assessed using appropriate semiquantitative scores at baseline and after 2 and 4\u00a0weeks. A second treatment cycle was applied if after 2\u00a0weeks the patient was not judged clinically cured.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> At week 2, a total of 75% (95% CI: 66\u201382%) and 71% (95% CI: 62\u201378%) of patients showed a complete clinical cure rate in the PF and BB groups, respectively. At week 4, the percentage of totally cured patients increased up to 95% (95% CI: 89\u201397%) and 91% (95% CI: 83\u201394%) in the PF and BB groups, respectively (<jats:italic>P\u00a0=<\/jats:italic>\u00a0NS between groups). At week 4, 5% in the PF group and 9% in the BB group complained of itching. Burning and irritation after treatment applications were more common in the BB group in comparison with the PF group. The tolerability score was better in the PF group in comparison with to BB group (2.9 vs. 2.2; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.0001). A total of 95% of patients in the PV group had a good tolerability score (i.e.\u00a0=\u00a03) in comparison with 41% in the BB group.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Our results show that a 3\u2010day treatment with pyrethrins thermofobic foam is at least as effective as a 5\u2010day treatment with benzyl benzoate lotion in convicted subjects with scabies. The foam formulation is better tolerated than the benzyl benzoate lotion.<\/jats:p>","DOI":"10.1111\/j.1468-3083.2006.01623.x","type":"journal-article","created":{"date-parts":[[2006,6,6]],"date-time":"2006-06-06T10:29:57Z","timestamp":1149589797000},"page":"717-720","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and tolerability of a new synergized pyrethrins thermofobic foam in comparison with benzyl benzoate in the treatment of scabies in convicts: the ISAC study (Studio Della scabbia in ambiente carcerario)"],"prefix":"10.1111","volume":"20","author":[{"given":"M","family":"Biele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Campori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"De Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Frascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Starnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Milani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The ISaC Investigator Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)09458-1"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1159\/000424240"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1754.2002.00015.x"},{"key":"e_1_2_6_5_2","first-page":"69","article-title":"Efficacy and tolerability of natural synergised pyrethrins in a new thermo labile foam formulation in topical treatment of scabies: a prospective, randomised, investigator\u2010blinded trial vs. permethrin cream","volume":"13","author":"Amerio PL","year":"2003","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_6_2","first-page":"331","article-title":"Comparison of ivermectin and benzyl benzoate for treatment of scabies","volume":"44","author":"Glaziou P","year":"1993","journal-title":"Trop Med Parasitol"},{"key":"e_1_2_6_7_2","first-page":"296","article-title":"The treatment of scabies with permethrin in comparison with blindane and benzyl benzoate","volume":"175","author":"Haustein UF","year":"1989","journal-title":"Dermatol Monatsschr"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330105"},{"key":"e_1_2_6_9_2","unstructured":"WalzerGJA JohnstonePW.Scabies.Cochrane Database Syst Rev2000: (2) CD000320."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-3083.2006.01623.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-3083.2006.01623.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T17:23:51Z","timestamp":1697045031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-3083.2006.01623.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,6]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["10.1111\/j.1468-3083.2006.01623.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-3083.2006.01623.x","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,6]]}}}